




Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma
Jensen, Frodi Fridason; Håkansson, Kjell E J; Overgaard Nielsen, Britt; Weinreich, Ulla
Møller; Ulrik, Charlotte Suppli
Published in:
Asthma research and practice







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Jensen, F. F., Håkansson, K. E. J., Overgaard Nielsen, B., Weinreich, U. M., & Ulrik, C. S. (2021). Self-reported
vs. objectively assessed adherence to inhaled corticosteroids in asthma. Asthma research and practice, 7(1), [7].
https://doi.org/10.1186/s40733-021-00072-2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: August 24, 2021
RESEARCH Open Access
Self-reported vs. objectively assessed
adherence to inhaled corticosteroids in
asthma
Frodi Fridason Jensen1†, Kjell E. J. Håkansson1*† , Britt Overgaard Nielsen2, Ulla Møller Weinreich2,3 and
Charlotte Suppli Ulrik1,4
Abstract
Background: Adherence to inhaled corticosteroids (ICS) in asthma is vital for disease control. However, obtaining
reliable and clinically useful measures of adherence remains a major challenge. We investigated the association
between patient-reported adherence and objectively measured adherence based on filled prescriptions with
inhaled corticosteroids in adults with asthma.
Methods: In total, 178 patients with asthma were asked to self-assess adherence during routine visits at a
respiratory outpatient clinic. Self-assessment was performed using Foster score (“How many days in a 7-day week do
you take your medication as prescribed?”, with the answer divided by 7). Objective adherence was calculated as
medication possession ratio (MPR). Bivariate and multivariable linear regression, adjusted for age, sex, FEV1, GINA
treatment step, excessive use of SABA, and history of exacerbations were used for analyses.
Results: Of the included patients, 87.6% reported a Foster score of 100%, while the mean ICS MPR was 54.0% (SD
25%). Complex regimens such as twice-daily dosing or dual inhaler-use were associated with lower adherence (p =
0.015 and p < 0.001, respectively).
Foster score was predictive of ICS MPR, with an absolute 32% increase in MPR between patients reporting Foster
scores of 0 and 100% (95% CI 13–50%, p < 0.001). Female sex predicted higher ICS MPR (p = 0.019). Previous
asthma-related hospitalization(s) predicted lower ICS MPR (p = 0.039).
Conclusion: Although a weak association was found between Foster score and ICS MPR, findings do not support
the use of Foster score, and by that self-reported adherence, as a reliable marker of controller adherence in asthma
due to significant mismatch between patient-reported adherence and MPR. Future studies should address the
complex interplay between patient-reported and objectively assessed adherence to controller medication in
asthma.
Keywords: Foster score, Medication possession ratio, Controller medication, Asthma, Self-assessed adherence,
Patient-reported outcome
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: kjell@kjell.dk
†Frodi Fridason Jensen and Kjell E. J. Håkansson contributed equally to this
work.
1Department of Respiratory Medicine, Copenhagen University Hospital -
Hvidovre, Hvidovre, Denmark
Full list of author information is available at the end of the article




Assessing adherence to ICS is central to asthma care
with a plethora of assessment methods, yet a lack of
standardization in clinical use. A verified, reliable
patient-assessed method with acceptable correlation to
objective measurements of adherence is yet to be estab-
lished. In Danish national guidelines, the one-item ques-
tionnaire Foster score is recommended for use in
adherence assessment without a clear correlation to clin-
ical outcomes.
What this paper contributes to our knowledge
Our findings suggest that the routinely used, patient-
reported Foster score correlates poorly to objective mea-
sures of adherence when used in clinical practice. Fur-
thermore, it builds on current evidence that objective,
clinical parameters are insufficient to explain patterns of
adherence. Furthermore, subjective factors and treat-
ment regimens are important elements in asthma con-
troller adherence and needs to be individually addressed
beyond the use of simple scores.
Introduction
Asthma is one of the most common chronic diseases
and impacts patients throughout their lives [1–3]. With
appropriate diagnostic workup and pharmacologic treat-
ment, a large proportion of patients can achieve symp-
tom control and a low risk of adverse events, such as
acute exacerbations. Treatment with inhaled corticoste-
roids (ICS) reduces symptoms, improves pulmonary
function parameters such as forced expiratory volume in
1 s (FEV1), reduces risk of future exacerbations and
asthma-related mortality [4–6]. However, adherence to
controller medication, including ICS, is highly variable
between asthma patients and is estimated to range be-
tween 22 to 70% of prescribed doses across different
settings [2, 7, 8]. Possible reasons for non-adherence to
asthma controller therapy are numerous and are often
related to lack of perceived need for treatment and/or ei-
ther fear of side effects or perceived side effects of ICS
treatment [9]. However, not all reasons for non-
adherence are based on personal beliefs or even
intentional, as social factors outside of the patient’s
own control, forgetfulness and misunderstandings
have been shown to be significant contributors to
non-adherence [7].
Low adherence to controller medication is associated
with poor disease control and adverse outcomes in
asthma. These include higher symptom burden, lower
FEV1 and higher risk of hospitalization-requiring exacer-
bations [2]. As such, it is vital to address poor adher-
ence, even though the complexity of factors associated
with reduced adherence is daunting to clinicians and
patients are reluctant to admit non-adherence [10].
Nonetheless, patients must be engaged in a discussion
during consultations, as improving adherence requires a
multimodal approach and establishing a partnership
with patients [11]. To this end, clinically reliable tools
for quick adherence assessments, both objective and
subjective, are needed.
Adherence can be estimated objectively using several
methods with electronic dose metering being the current
gold standard for ICS adherence measurement [12, 13].
The Medication Possession Ratio (MPR), based on pre-
scription data, is another method for measuring object-
ive adherence, one that does not require access to
specialized inhaler equipment. With regard to patient-
reported adherence, the Danish Society of Respiratory
Medicine’s Guidelines on Possible Severe Asthma rec-
ommends the systematic use of Foster score when asses-
sing adherence [14]. The Foster score was developed as
a simple, non-confrontational, one question scoring
method for quick assessment based on the Morisky
medication-taking behavior scale [9, 15]. However, its
clinical value and relationship to objective adherence
measurement remains unclear.
In the present study, we aimed to investigate the cor-
relation between patient reported adherence assessed by
Foster score and the objectively measured MPR in a uni-
versity hospital asthma outpatient clinic.
Methods
Design, Study Population & Participant Enrolment
This study is a cross-sectional observational study car-
ried out in the Respiratory Outpatient Clinic, Depart-
ment of Respiratory Medicine, Copenhagen University
Hospital - Hvidovre, Hvidovre, Copenhagen, Denmark.
All patients with a routine follow-up appointment be-
tween January and June 2020 at the Respiratory Out-
patient Clinic with an active asthma ICD-10 code (DJ45)
were screened for inclusion using electronic patient
medical records. Cohort inclusion required the following
criteria: i) objectively confirmed asthma for at least 12
months prior to inclusion ii) at least 18 years of age. Ex-
clusion criteria were as follows: i) patients prescribed
ICS for less than 12months at the index date, ii) recipi-
ents of dose dispensed medications via assisted care, iii)
the inability to answer the questionnaire due to any psy-
chological or physical limitations and iv) non-Danish
residents without a Danish civil registration number and
corresponding Common Medication Card.
Ethics
The present study was approved by the Danish
Patient Safety Authority (ref. 31–1521-118) and the
Capital Region of Copenhagen’s Data Monitoring
Board (ref. P-2020-648).
Jensen et al. Asthma Research and Practice             (2021) 7:7 Page 2 of 9
Data collection
Data for age, sex, body mass index (BMI), Fractional
Exhaled Nitric Oxide (FeNO), lung function parameters
(FEV1, FEV1%pred, Forced Vital Capacity (FVC) and
FVC%pred) and Asthma Control Questionnaire 6-score
(ACQ6) was collected through electronic medical
records (Sundhedsplatformen, Epic Systems Inc., USA).
Asthma exacerbation data was collected from elec-
tronic patient journals using the following definitions: i)
Moderate exacerbation – either prescription of at least
37.5 mg oral prednisolone for at least 3 days not coincid-
ing with a hospitalization, or hospitalization/emergency
room admittance for less than 24 h. ii) Severe exacerba-
tion – any exacerbation requiring hospitalization for at
least 24 h and administration of oral or intravenous
corticosteroids.
Spirometry
Lung function was measured using a Pneumotrac (Vita-
lograph Ltd., Buckinghamshire, UK) spirometer as part
of standard of care at the respiratory outpatient clinic.
Allergies
Patients were considered to have allergic disease when
1) relevant symptoms and 2) relevant diagnostic workup
(either positive skin prick test, blood samples positive
for elevated specific Immunoglobulin E (IgE) or elevated
total-IgE) were described in the electronic patient
records.
Prescription data
Pharmacy redemption data was collected for each
patient from the national Common Medication Card,
the national prescription register for the tax-funded uni-
versal healthcare insurance in Denmark. ICS, long-acting
β2-agonist (LABA), long-acting muscarinic receptor an-
tagonist (LAMA), leukotriene-receptor antagonist
(LTRA), short-acting β2-agonist (SABA), theophylline,
biologic therapy (anti-IL5(Ra), anti-IL4/13 and anti-IgE),
oral corticosteroid (OCS) doses and proton-pump in-
hibitor (PPI) use was registered for 12 months prior to
the index date.
Daily prescribed ICS dose was categorized according
to the GINA 2020 guidelines [6]. Objective controller
medication adherence (MPR) was calculated as the num-
ber of physician prescribed doses during the previous 12
months, divided by the number of redeemed doses dur-
ing the previous 12 months [16]. During MPR calcula-
tions, the following adjustment were performed i)
Patients prescribed two ICS inhalers were considered to
be adherent to treatment if both doses were available for
use at the same time. ii) For patients with dual ICS ther-
apy prescriptions, only redeeming one of the ICS during
the observation period, MPR was calculated as single
ICS MPR for the inhaler redeemed and reduced by 50%
to reflect non-adherence. iii) Patients changing inhalers
during the observation period had the remainder of
doses in the discontinued inhaler at the date of discon-
tinuation discarded to prevent inflation of MPR.
Patient reported adherence
Ten modifiable patient beliefs or behaviors regarding ad-
herence to ICS has been identified by Foster and col-
leagues [9]. Based on the results of Foster et al. [9], a so-
called Foster score has been adapted and recommended
by the Danish Society of Respiratory Medicine Guide-
lines using the question “How many days in a 7-day
week do you take your medication as prescribed?”. The
Foster score is achieved by dividing the patients’ answer
by seven and multiplying by 100. The resulting Foster
score ranges from 0% (completely non-adherent) to
100% (fully adherent).
Inhaler technique
All patients enrolled had inhaler technique, including in-
spiratory flow and device handling, assessed at both the
index visit as well as any prior visits to ensure proper in-
haler use.
Statistics
Descriptive statistics were used to generate demographic
data, with the results presented as means with standard
deviations (SD). Groupwise comparisons, including non-
responder analyses, were performed using either t-tests
or Wilcoxon rank-sum tests, depending on the distribu-
tion of the data.
Non-responder analyses were performed, comparing
demographics and asthma-related parameters of patients
who provided clinicians with a Fosters score to those
whose Foster scores were not recorded in their patient
records.
Bivariate and multivariable linear regressions were per-
formed to investigate the association between Foster
score and MPR. Multivariable linear regression analyses
were adjusted for age, FEV1, sex, GINA 2020 treatment
step [6] number of hospitalizations due to asthma the
past 24 months, prescribed oral corticosteroids and
SABA overuse (defined as ≥600 doses per year).
Explorative multivariable linear regression was per-
formed to assess the influence of common comorbidities
and subjective disease control on Foster scores and ICS
MPR. The model was adjusted for age, sex, ACQ6, BMI,
GERD (Gastroesophageal reflux disease, defined as PPI-
use at the index visit) and allergy. A p-value of 0.05 was
considered as statistically significant.
R 4.0.0 (The R Foundation for Statistical Computing)
was used for statistical analysis and to generate figures.
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Results
A total of 400 patients were screened in the respiratory
outpatient clinic during the inclusion period, of which
313 were eligible for the study. Out of the 313 eligible
patients, 135 patients failed to supply Foster scores dur-
ing consultations and were thus excluded. The final co-
hort comprised of 178 patients, of whom 136 (76.4%)
were female, and the mean age was 47 (SD 16)
(Table 1).
Lung function, comorbidities and asthma severity
In the final cohort, mean FEV1 was 91%pred (SD 18),
corresponding to 2.79 L (SD 0.80) (Table 1). Mean BMI
and FeNO were 27.6 (SD 5.8) and 20.3 ppb (SD 18.9), re-
spectively. Fifty-nine patients (36.7%) were classified as
having allergic disease and 41 patients (23.0%) were pre-
scribed PPI for GERD.
When classified according to GINA 2020 severity 15
(8.4%), 60 (33.7%) and 103 (57.9%) were classified as
mild, moderate and severe, respectively (Table 1).
Regarding ICS doses, medium and high doses were pre-
scribed to 71 (39.9%) and 41 (23.0%) patients, respect-
ively (Table 2).
Asthma control
In terms of disease control, 43 (24.2%) patients had had
moderate exacerbations during the past 24 months.
For patients with at least one moderate exacerbation,
the mean 24-month moderate exacerbation rate was
1.77 (SD 1.27).
Of the included patients, 23 had been hospitalized due
to an asthma exacerbation with a mean 24-month
hospitalization rate of 1.65 (SD 1.50).
The mean annual SABA use was 255 (SD 445) doses/
year, with 18.0% of patients defined as having an exces-
sive SABA use above 600 doses/year (Table 2).
Table 1 Baseline characteristics of the study sample comprising
178 patients with asthma managed at a university hospital
respiratory outpatient clinic
Baseline Characteristics N (%) or Mean (SD)
Age (yrs.) 47 (16)
Female 136 (76.4%)
ACQ6-score 1.32 (1.07, N = 114)
FeNO 20.3 (18.8, N = 164)
BMI 27.6 (5.8, N = 176)
Allergic Disease 59 (36.7%, N = 164)
GERD 41 (23.0%)
FEV1 (L) 2.79 L (0.80)
FEV1%pred 91% (18%)
FVC (L) 3.67 L (1.02, N = 169)
FVC%pred 102% (20, N = 169)
FEV1/FVC 0.76 (0.09, N = 169)
History of Moderate Exacerbations* 43 (24.2%)
24-month Moderate Exacerbation Rate 1.77 (1.27)
History of Severe Exacerbations** 23 (12.9%)
24-month Severe Exacerbation Rate 1.65 (1.50)
GINA 2020 Asthma Severity Grade
Mild Disease 15 (8.4%)
Moderate Disease 60 (33.7%)
Severe Disease 103 (57.9%)
*defined as either prescription of at least 37.5 mg oral prednisolone for at least
3 days, or hospitalization/emergency room admittance for less than 24 h in the
last 24months prior to inclusion. **defined as any exacerbation requiring
hospitalization for at least 24 h and administration of oral or intravenous
corticosteroids. N number of patients, yrs. years, ACQ Asthma Control
Questionnaire, BMI Body Mass Index, FeNO Fractional Exhaled Nitric Oxide,
FEV1 Forced Expired Volume in the first second, GERD Gastroesophageal Reflux
Disease, GINA Global Initiative for Asthma
Table 2 Treatment regimens and patient-reported and
objectively measured asthma medication adherence in 178
patients attending a university hospital outpatient clinic
Treatment and Adherence N (%), Mean (SD)
ICS Prescribed Dose
Low Dose 66 (37.1%)
Moderate Dose 71 (39.9%)
High Dose 41 (23.0%)
Dual ICS Therapy 32 (18.0%)
GINA 2020 Step
Step 2 15 (8.4%)
Step 3 60 (33.7%)
Step 4 62 (34.8%)
Step 5 41 (23.0%)
Biologic Therapy 3 (1.7%)
Maintenance Oral Corticosteroids 6 (3.4%)
Annual SABA Use (Doses) 255 (445)
of which > 600 doses/yr 32 (18.0%)
Foster Score 94.0% (19.0%)
of which 100% 156 (87.6%)
Inhaled Corticosteroid MPR 0.54 (0.25)
Once-daily ICS MPR (n = 19) 67.0% (13.1%)
Twice-daily ICS MPR (n = 127) 53.4% (25.2%, p = 0.05*)
Dual ICS MPR (n = 32) 43.9% (26.0%, p = 0.02*)
ICS Adherence
80% or above 30 (16.9%)
Below 80% 148 (83.1%)
* Versus patients receiving once-daily ICS. N number of patients, IQR inter-
quartile range, ICS Inhaled Corticosteroids, GINA Global Initiative for Asthma
(2020), MPR medication possession ratio, LABA long-acting β2-agonist, LAMA
long-acting muscarinic receptor antagonist, SABA short-acting β2-agonist, MPR
medication possession ratio, SD standard deviation
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Adherence measurements
In terms of patient-assessed adherence, the mean re-
ported Foster score was 94.0% (SD 19.0%) with 156
(87.6%) patients reporting the best possible Foster score.
Corresponding objective adherence was a mean ICS
MPR of 54.0% (SD 25.0%), with 16.9% of patients
deemed as being objectively adherent (ICS MPR
above 80%).
When stratified by ICS treatment regimen as once-
daily, twice-daily or dual ICS, the mean ICS MPR was
significantly lower in both twice-daily and dual ICS-
regimens when compared to patients receiving once-
daily ICS-formulations (Table 2).
Correlation between MPR and patient reported adherence
In bivariate regression analysis, a significant association
between MPR and Foster score was demonstrated, with
an absolute 36% MPR difference (Beta 0.36, 95% CI
0.18–0.54; p < 0.001) between patients reporting Foster
scores 0 and 100%. However, the model fit was poor (R2
0.082), even though the overall model demonstrated a
significant p-value of < 0.001 (Fig. 1).
In multivariable analysis adjusted for age, FEV1,
sex, GINA 2020 treatment step, history of moderate
and severe exacerbations in the past 24 months and
excessive SABA use, Foster score remained statisti-
cally significantly associated with ICS MPR, with an
absolute MPR increase of 32% between patients
reporting a Foster score of 0 and 100% (Beta 0.32,
95% CI 0.13–0.50; p < 0.001). Female sex was associ-
ated with a higher ICR MPR (0.12, 95% CI 0.02–
0.22; p = 0.019) while a history of severe exacerba-
tions the past 24 months was associated with a lower
ICS MPR (− 0.12, 95% CI -0.24 - -0.01, p = 0.039).
Additionally, a trend towards a higher MPR with
increasing FEV1 was found (0.05, 95% CI -0.01 -
0.11, p 0.079). The overall model achieved an
adjusted R2 of 0.149 with a corresponding p-value of
0.001 (Table 3).
Explorative analyses
In multivariable linear regression adjusted to investigate
correlation between ICS MPR, Foster score and the role
of comorbidities and patient-reported disease control,
Foster score remained associated with ICS MPR though
with a neutral beta (0.00, 95% CI 0.00, 0.01; p = 0.006).
Of the chosen covariates (age, sex, ACQ6, BMI, GERD
and allergic disease) only GERD was significantly associ-
ated with ICS MPR (Beta − 0.13, 95% CI -0.25, − 0.01;
p = 0.040) (Table 4).
Non-responder analyses
Of patients screened for inclusion, participating patients
were more likely to be younger, have a slightly lower

























Fig. 1 Distribution of ICS MPR and Foster scores for 178 patients attending a university hospital respiratory outpatient clinic, as well as a linear
regression on the relationship between ICS MPR and Foster scores. R2 = 0.082
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differences in objective disease control measurements or
adherence to ICS were found (Supplementary Table 1).
Discussion
This study sought to investigate the relationship between
patient-reported adherence and objective adherence
measured by MPR for the past 12 months. Patient-
reported adherence was high with a mean of 94.0% and
was significantly associated to ICS MPR, though demon-
strating a weak direct correlation with overall MPR
scores.
We have shown a high prevalence of patients reporting
perfect adherence with a Foster score of 100% despite
high MPR variance (MPR range 0.0–99.7%). Patient
overestimation of adherence is probable, as a significant
portion of patients who reported a Foster score of 100%
did not have a corresponding MPR above 80%. Indeed,
patient-assessed adherence is vulnerable to social desir-
ability bias and unintentional non-adherence. In accord-
ance with our findings, several studies have found
patient-reporting to inflate ICS adherence rates by 30–
90% [17–19] and similar effects are seen in other chronic
diseases [20, 21].
For a patient to be considered adherent, a MPR
threshold of 80% or higher is typically required [2, 22,
23]. In the present study, objectively measured mean ad-
herence (MPR) was in line with previous studies ranging
from 8 to 70% [2, 19, 24, 25]. However, we observed a
disparity between the number of patients reporting per-
fect adherence using Foster score (87.6%) and objectively
measured acceptable (MPR ≥80%) adherence (16.9%).
Such discrepancies are well described in the literature
[17], signaling a difference in what is deemed an accept-
able level of medication use between clinicians and pa-
tients, while highlighting the importance of establishing
a partnership with patients and engaging in deeper con-
versations regarding the use of ICS.
The high prevalence of perfect adherence reported
by patients challenges the use of correlation and re-
gression statistics due to high homogeneity and
resulting lack of variance and highlights a major
weakness in clinical use of the Foster score and limits
applicability. However, both regression models dem-
onstrated significant, yet weak, relationships between
ICS MPR and Foster score and explained variability
Table 3 Bivariate and multivariable linear regressions with ICS MPR as outcome variable and Foster score, age, FEV1, sex, GINA 2020
treatment steps, exacerbation history and excessive SABA use as exposure variables
Variable Bivariate Multivariable
Beta 95% CI P-value Beta 95% CI P-value
Foster Score 0.36 (0.18–0.54) < 0.001 0.32 (0.13–0.50) < 0.001
Age 0.00 (0.00–0.00) 0.2
FEV1 0.05 (-0.01–0.11) 0.079
Female 0.12 (0.02–0.22) 0.019
GINA 2020 Step
Step 2 – – –
Step 3 0.02 (-0.11–0.16) 0.8
Step 4 0.10 (-0.04–0.24) 0.2
Step 5 0.08 (-0.08–0.24) 0.3
History of Moderate Exacerbations# 0.00 (-0.09–0.10) > 0.9
History of Severe Exacerbations## -0.12 (-0.24–-0.01) 0.039
Excessive SABA use (above 600 doses/yr) 0.06 (-0.04–0.16) 0.3
R2 = 0.082. Adjusted R2 = 0.149. FEV1 Forced Expired Volume in the first second, GINA Global Initiative for Asthma (2020),
#defined as either prescription of at least
37.5 mg oral prednisolone for at least 3 days, or hospitalization/emergency room admittance for less than 24 h in the last 24 months prior to inclusion. ##defined
as any exacerbation requiring hospitalization for at least 24 h and administration of oral or intravenous corticosteroids, SABA Short-acting beta 2-agonist
Table 4 Multivariable linear regression with ICS MPR as
outcome variable and Foster score, age, sex, ACQ6 and
common comorbidities (BMI, GERD and allergies) as exposure
variables
Variable Multivariable
Beta 95% CI P-value
Foster Score 0.00 (0.00–0.01) 0.006
Age 0.00 (0.00–0.01) 0.061
Female 0.04 (-0.07–0.15) 0.4
ACQ6 0.01 (-0.04–0.05) 0.8
BMI 0.00 (-0.01–0.01) 0.6
GERD −0.13 (-0.25–0.01) 0.040
Allergy 0.06 -0.05–0.17 0.3
Adjusted R2 = 0.155. ACQ6 Asthma Control Questionnaire 6, BMI Body Mass
Index, GERD Gastroesophageal reflux (Proton-pump inhibitor-use), Allergy
(Relevant symptoms plus either positive skin prick test or elevated specific
Immunoglobulin E)
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measured by R2 values were low, reaching approxi-
mately 15% in the multivariable model. Foster and
colleagues previously investigated the relationship be-
tween ICS-related beliefs and MPR and demonstrated
that an 11-item model explained two thirds of object-
ive adherence to ICS [9], suggesting that psycho-
logical factors represent a larger portion of overall
adherence-deciding factors than clinical parameters
used in the present study. Other studies have demon-
strated that other patient-specific factors, such as so-
cioeconomic status and comorbidity burden, have
profound effects on adherence [7, 26]. Indeed, clinical
adherence assessment should include multiple do-
mains, both objective and subjective. Such tools are
in continuous development, and the Test of Adher-
ence to Inhalers is a validated example of a multi-
domain adherence assessment tool [27].
In regression analyses, a history of previous severe ex-
acerbations within the last 24 months was significantly
associated with lower adherence. In contrast to a history
of severe exacerbations, a history of moderate exacerba-
tions within the last 24 months was not significantly as-
sociated with adherence. This suggests that within this
population a higher adherence primarily protects against
severe exacerbations. The protective effect of ICS adher-
ence on severe exacerbations has been well established
[2, 28], but recent results and differences in adherence
and exacerbation definitions cast doubt on the relation-
ship between adherence, exacerbation history and the
risk of future severe, hospitalization-requiring exacerba-
tions [29].
Interestingly, our data suggests that practical factors
are associated with adherence, as patients with less com-
plex treatment regimes, such as once-daily dosage, dem-
onstrate a higher MPR than those with twice-daily
dosing. Furthermore, the use of more than one ICS in-
haler was associated with a lower MPR. This has previ-
ously been reported in a plethora of chronic diseases
treated with oral medications, showing that one pill
taken once-daily is associated with the highest adherence
[30]. As such, practical factors are important pieces in
the adherence puzzle beyond classic psychological and
clinical factors. As such, clinicians should not only take
beliefs and disease severity into account when prescrib-
ing inhaler treatments, but also gauge individual pa-
tients’ ability to follow complex regimens.
There are several caveats to using MPR as a meas-
urement of objective adherence. First, the Foster score
is a time-agnostic measurement, while MPR always
takes a retrospective long-term perspective, demon-
strated in the present article by 5 patients reporting a
Foster score of 0 while having an MPR above 0. Sec-
ond, depending on the chosen methodology MPR
measurements are sensitive to inflation when
generated from pharmacy records [31]. MPR inflation
can occur due to changes in inhaler therapy shortly
after treatment initiation, unadjusted dual-ICS therapy
(such as a combination of moderate doses of flutica-
sone and ciclesonide) and redemption of multiple ICS
inhalers to use as backup. However, in the present
study, MPR inflation has been mitigated in part due
to adjusting for inhaler changes by removing excess
doses after the physician-ordered discontinuation date,
dual-ICS adjustment as well as MPR capping. The use
of MPR capping has been thoroughly discussed, with
previous studies reporting limited significance of
capping MPR, especially in contrast to other
adherence measurements such as proportion of days
covered [9, 32].
Limitations
Several limitations exist in this study. First, the study
covers a set of objective and subjective adherence mea-
surements, reducing generalization to other methods of
assessing adherence. Second, while prescription data are
accurate in measuring the number of doses redeemed,
there is a risk of redeemed doses remaining unused by
the patient either due to low adherence or due to a
change in medication regimens. Poor inhaler technique
may lead to administered but theoretically lower doses
which cannot be assessed using MPR, though all outpa-
tients are provided with inhaler training as part of every
outpatient visit at the study center. Due to the study de-
sign, patients redeeming inhalers in bulk may be either
under- or overestimated in terms of number of
redeemed doses, should the patient have redeemed mul-
tiple prescriptions just outside the study period. Pre-
scription auto-refills are unavailable in Denmark, but
have previously been shown to affect adherence with
long-term medications and external validity may thus be
limited [33]. Furthermore, the cohort has a high preva-
lence of female participants increasing the risk of bias,
though the role of sex in adherence is debated [34] and
sex is adjusted for in multivariable analyses. Finally,
slight differences between responders and non-
responders was found, however with a large span and
with most variables below clinical differences. Outcome
measurements such as objective disease control and
MPR were not found to be differing between responders
and non-responders.
Conclusion
While a significant association between Foster score and
medication possession ratio with inhaled corticosteroids
was found, our findings do not support the use of Foster
score as the sole marker of adherence with controller
medication in asthma. Future studies should address the
complex interplay between self-reported and objectively
Jensen et al. Asthma Research and Practice             (2021) 7:7 Page 7 of 9
assessed adherence with controller medication in
asthma.
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